Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia

  • Read more about Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia

SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

  • Read more about SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

Effect of a Health Pathway for People With Persistent Symptoms Covid-19

  • Read more about Effect of a Health Pathway for People With Persistent Symptoms Covid-19

Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults

  • Read more about Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults

Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults

  • Read more about Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults

Extrapulmonary Presentations of COVID-19 Patients

  • Read more about Extrapulmonary Presentations of COVID-19 Patients

INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old

  • Read more about INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old

Neurobiological Underpinnings of Neuropsychological Consequences in Long COVID

  • Read more about Neurobiological Underpinnings of Neuropsychological Consequences in Long COVID

Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).

  • Read more about Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

  • Read more about Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 121
  • Page 122
  • Page 123
  • Page 124
  • Current page 125
  • Page 126
  • Page 127
  • Page 128
  • Page 129
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA